# KPV Current Availability at telos rx **By TelosRX Editorial Team** · 2026-09-21 **KPV is not currently offered by telos rx for compounding. This page states that plainly and explains exactly where the peptide stands in telos rx's review process, without implying a timeline or a workaround.** What to know telos rx does not currently offer KPV for compounding. It remains under internal review rather than part of the current program. You can read more about telos rx's current status on [KPV here](https://www.telosrx.com/pages/kpv). ## The short version If you came here to find out whether you can start KPV through telos rx today, the answer is no. It is not sold, not stocked, and not offered as part of any protocol. There is no waitlist for it and no estimated launch date, because none has been set. That is true even though search interest in the peptide has grown steadily. This is not a statement about whether KPV works or does not work. It is a statement about where telos rx's compounding program currently stands, which is a separate question from the underlying science. ## What this page will and will not do This page will tell you plainly what telos rx offers and does not offer, and why. It uses the true reasons rather than a vague placeholder. It will not speculate about a launch window, imply a workaround, or suggest that availability is close simply because interest is high. ## Why availability and evidence are different questions It is easy to assume that if a peptide is not offered, it must be because it failed some kind of test. That is not accurate here. telos rx's decision not to offer KPV reflects where its internal review process stands, not a conclusion that the peptide is unsafe or ineffective. A compounding pharmacy program has to weigh several factors before adding any new peptide. Classification status, sourcing from licensed pharmacies, consistency of preparation standards, and how confidently a provider can evaluate a patient all matter. KPV has not cleared that bar yet at telos rx, and there is no way to predict when, or if, it will. ## What "under review" actually means telos rx maintains a running review of research peptides, including KPV, MOTS-C, semax, GHK-Cu, ipamorelin, 5-amino-1MQ, and epitalon, for potential future inclusion in its compounding program. Being under review means the peptide is being tracked and evaluated, not that it is queued for a release date. A 2026 committee review, known as PCAC, issued non-binding recommendations touching on several research peptides in this category. That was a recommendation from an advisory body, not a regulatory approval, and it did not change what any compounding pharmacy is currently permitted to prepare. telos rx has not added KPV to its offerings as a result of that review. **Key takeaway:** "Under review" is an honest, ongoing status, not a soft promise. There is no confirmed date for KPV joining the program, and this page will not pretend otherwise. ## What telos rx does offer today While KPV is not available, telos rx does run an active compounded peptide program built on substances that have cleared internal review. That includes BPC-157, PT-141, NAD+ nasal spray, and sermorelin, each sourced through partner compounding pharmacies and reviewed by a licensed provider before any prescription is issued. These are not substitutes for KPV in a clinical sense. They are simply the peptides telos rx can responsibly offer right now, following the same review standard that KPV has not yet cleared. ## The regulatory backdrop, briefly Compounded medications broadly are not FDA-approved. They are prepared by licensed pharmacies under federal compounding rules that govern which substances can be compounded and under what conditions. The FDA publishes a general overview of how this works, available on its [compounding questions and answers page](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers). Peptides like KPV sit in a gray area of this framework. There is real scientific interest in the molecule, documented in laboratory and animal research summarized by the [National Institutes of Health](https://pmc.ncbi.nlm.nih.gov/articles/PMC2095288). Interest and evidence are not the same as a clear regulatory pathway for pharmacy compounding. That gap is exactly what telos rx's review process is meant to sort through. ## What would change this page Two things could shift KPV's status. The first is a clearer regulatory classification that gives compounding pharmacies confidence about what they are permitted to prepare. The second is telos rx's own internal review concluding that the peptide meets its standards for sourcing, dosing guidance, and provider oversight. Neither of those has happened. Until one or both do, telos rx will keep this page accurate rather than optimistic, which means continuing to say plainly that KPV is not currently offered. ## How to stay informed without guessing If you want to track KPV's status honestly, the most reliable approach is to check back on this page or telos rx's dedicated KPV page. Forum chatter tends to run ahead of what is actually confirmed. Sellers outside licensed pharmacy channels sometimes imply availability that does not reflect any real regulatory clearance. telos rx will update its own pages if and when KPV's status changes. There is no subscription or notification list to join for this specific peptide right now, and no reason to assume a change is imminent simply because interest is high. ## How telos rx decides what to add telos rx does not treat every peptide the same way once it has cleared regulatory questions. Each candidate goes through an internal review. It looks at the strength of available research, how consistently a compounding pharmacy can prepare it, and whether a provider can meaningfully screen a patient before approving it. That process is deliberately slower than simply reacting to search volume or social media interest. A peptide can be widely discussed online and still not meet the bar telos rx sets for adding something to an active compounding program. KPV is currently in that position. None of this is unique to KPV. The same review applies to MOTS-C, semax, GHK-Cu, ipamorelin, 5-amino-1MQ, and epitalon, all of which are also under review rather than offered today. ## What patients sometimes get wrong about "under review" A common misunderstanding is treating "under review" as a soft promise of imminent release. It is not. telos rx uses that phrase because it is accurate, not because it is a softer way of saying yes. There is no internal launch date being withheld from this page. If telos rx had a confirmed timeline for KPV, this article would say so directly. The honest answer right now is that no such timeline exists, and speculating about one would not serve anyone reading this to make a real decision about their care. ## What this means if you already use KPV informally Some readers arrive at this page already sourcing KPV outside a licensed pharmacy. telos rx is not able to review, dose, or oversee anything obtained that way, and doing so carries real risk regardless of what any seller claims about purity or sourcing. If you are currently using any unregulated peptide, telling your provider matters more than deciding whether to stop or continue. A provider can only give you meaningful guidance about interactions, dosing, or side effects if they know the full picture of what you are taking. ## How telos rx's status pages stay current telos rx reviews its research-peptide status pages on a recurring basis rather than leaving them static. That review checks for any change in regulatory classification, any update from internal compounding review, and any development worth reflecting here. When a peptide's status changes, the update happens on the peptide's own page and on any related articles like this one. There is no separate mailing list for individual peptide updates, and telos rx does not send speculative notices about pending changes before they are confirmed. ## Which is right for you If you are looking to start a compounded peptide protocol today, telos rx currently offers [BPC-157](https://www.telosrx.com/pages/bpc-157), [PT-141](https://www.telosrx.com/pages/pt-141), [NAD+ nasal spray](https://www.telosrx.com/pages/nad-nasal-spray), and [sermorelin](https://www.telosrx.com/pages/sermorelin). BPC-157 is the closest currently available option for anyone drawn to KPV's studied gut and tissue-repair signaling. [Start your BPC-157 intake →](https://start.telosrx.com/start-online-visit/peptides) ## Frequently Asked Questions ### Does telos rx currently sell KPV? No. KPV is not currently offered by telos rx for compounding. It is not stocked, not sold, and not part of any active protocol. ### Is KPV coming to telos rx soon? There is no confirmed timeline for KPV joining telos rx's compounding program. It remains under internal review, and this page does not imply any specific date. ### Why isn't KPV available if people are asking for it? Demand alone does not determine what a compounding program offers. telos rx requires a peptide to clear internal review covering sourcing, classification, and provider oversight, and KPV has not cleared that review yet. ### Is KPV FDA-approved? No compounded peptide, including KPV, is FDA-approved. Compounded medications broadly are not FDA-approved, and KPV specifically is not offered by telos rx at all right now. ### What did the 2026 PCAC review actually decide about KPV? The 2026 PCAC review issued non-binding recommendations about a group of research peptides. That is advisory input, not a regulatory approval, and it did not change telos rx's current offerings. ### What can I start today instead? telos rx currently offers BPC-157, PT-141, NAD+ nasal spray, and sermorelin, all compounded through partner compounding pharmacies and reviewed by a licensed provider through an asynchronous intake. _telos rx is LegitScript-certified. Compounded medications are not FDA-approved and are prepared by partner compounding pharmacies under federal compounding regulations. KPV is not currently offered by telos rx. This article is general information, not medical advice, and does not replace guidance from your own provider. Approval for any compounded medication is subject to evaluation by a licensed provider, and approval is not guaranteed._ Questions about what telos rx currently offers? [Visit telos rx](https://telosrx.com) to see available peptide protocols. --- > Source: [Telos RX](https://www.telosrx.com/blogs/glp1/kpv-current-availability-at-telos-rx)